Analysts Offer Predictions for AUPH Q1 Earnings

Key Points

• Leerink Partners forecasts Aurinia Pharmaceuticals (AUPH) to post $0.15 earnings per share for Q1 2026, with full-year estimates of $0.65 EPS for 2026 and $0.77 EPS for 2027.
• Aurinia's recent earnings report revealed a net margin of 23.31% and a revenue of $70.01 million, exceeding analyst expectations of $64.27 million.
• Institutional investors have recently increased their stakes in Aurinia, with notable increases from GF Fund Management and Tower Research Capital.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Investment analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Aurinia Pharmaceuticals in a research note issued on Thursday, July 31st. Leerink Partnrs analyst J. Schwartz expects that the biotechnology company will post earnings of $0.15 per share for the quarter. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals' Q2 2026 earnings at $0.17 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.65 EPS and FY2027 earnings at $0.77 EPS.

Several other equities research analysts also recently commented on AUPH. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH traded down $0.21 during midday trading on Monday, hitting $11.41. The company's stock had a trading volume of 1,786,689 shares, compared to its average volume of 1,590,286. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. Aurinia Pharmaceuticals has a fifty-two week low of $5.29 and a fifty-two week high of $11.80. The stock's 50 day simple moving average is $8.56 and its 200 day simple moving average is $8.21. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 26.57 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Nuveen LLC bought a new position in Aurinia Pharmaceuticals during the 1st quarter worth about $10,014,000. Tang Capital Management LLC increased its holdings in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after purchasing an additional 1,200,000 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $9,662,000. Point72 Asset Management L.P. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $7,630,000. Finally, Jupiter Asset Management Ltd. purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth about $6,052,000. Institutional investors own 36.83% of the company's stock.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 200,000 shares of the company's stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the transaction, the director directly owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This represents a 1.80% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought a total of 1,300,000 shares of company stock worth $13,590,000 over the last three months. Insiders own 12.20% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.